News

LEUKEMIA 360 will be held on 13 November 2024 at the Centre de Conférence Pierre Mendès France organised bu Carnot OPALE.

Carnot I2C, STAR and 3BCAR are joining forces for the 10th COSMETIC 360, the world innovation trade fair for the perfume and cosmetics industry, to be held in Paris on 16 and 17 October 2024.

Carnot Chimie Balard Cirimat, Icéel, Ingénierie@Lyon, M.I.N.ES, MICA, are taking part in LuxePack 2024 on the 30th September to 2nd October 2024 on a joint stand. 

Carnot CEA List and Thales announce the signature of their new partnership in the field of generative artificial intelligence (AI). Gathered within cortAIx, Thales' AI accelerator for mission-critical systems, the Group's AI research teams will collaborate with those of CEA List to provide sovereign, controlled and trusted AI solutions.

As they get older, the elderly are often forced to give up owning a pet, despite the benefits of such a relationship. What if technology could help preserve this precious bond? This could potentially slow down the loss of autonomy.  This is the subject of Hazar Zilelioglu's thesis, which brings together academic and industrial partners, with the support of Carnot TSN.

Paris (France), April 25, 2024 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer center, today announced the dosing of the first patients in a Phase Ib clinical trial evaluating PEP-Therapy’s lead candidate, PEP-010, based on highly encouraging Phase Ia results. This second part ot the Phase I study is evaluating PEP-010 in combination with chemotherapy (paclitaxel or gemcitabine), in advanced or metastatic ovarian cancer (OC) and in metastatic pancreatic ductal adenocarcinoma (PDAC), two indications with high unmet medical need.

The Carnot provide advanced technologies to more than 100 Deeptech start-ups per year.

Catherine Plessy succeeds Hubert Chameaud as Deputy Director General of the Association of Carnot Institutes (AiCarnot). She was previously responsible for the partnership development of the Carnot Icéel.

Partners since 2019, Institut Curie and Biomunex announce a new stage in their strategic research collaboration. Already co-inventor and 50% co-owner of this approach, Biomunex has signed an exclusive licensing agreement with Institut Curie for the clinical development of a new class of antibodies, capable of specifically targeting, engaging and redirecting MAIT cells to destroy cancer cells. A further step towards new, safer and more effective cutting-edge immunotherapies for the benefit of patients.

Under the effects of climate change, weather events are becoming more frequent and intense in terms of loss experience and damage costs. Lightweight structures such as houses and houses and roads, built on very plastic clay soils and sensitive to the shrinkage and swelling phenomena, suffer more degradations due to drought.
The Cerema, Institut Carnot Institute Clim'adapt, works and mobilizes those concerned to develop new remedial solutions to reduce the vulnerability of buildings exposed to the RGA and its resilience to climate change.

Neuroscientists and neurosurgeons from EPFL/CHUV/UNIL and CEA/FDD Clinatec/CHUGA/UGA report in the journal Nature that they have re-established the communication between the brain and spinal cord with a wireless digital bridge, allowing a paralyzed person to walk again naturally.

AVATAR MEDICAL helps surgeons better prepare their procedures through the use of virtual reality (VR) representations of their patients. These patient avatars are generated instantly from CT scan or MRI images with an underlying proprietary technology based on four years of research in human-data interaction and machine learning conducted at Institut Curie and Institut Pasteur (both Carnot Institute)